CL2024000580A1 - Vectores de hcmv recombinante y usos de estos - Google Patents
Vectores de hcmv recombinante y usos de estosInfo
- Publication number
- CL2024000580A1 CL2024000580A1 CL2024000580A CL2024000580A CL2024000580A1 CL 2024000580 A1 CL2024000580 A1 CL 2024000580A1 CL 2024000580 A CL2024000580 A CL 2024000580A CL 2024000580 A CL2024000580 A CL 2024000580A CL 2024000580 A1 CL2024000580 A1 CL 2024000580A1
- Authority
- CL
- Chile
- Prior art keywords
- recombinant hcmv
- hcmv vectors
- vectors
- recombinant
- hcmv
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239298P | 2021-08-31 | 2021-08-31 | |
| US202263356386P | 2022-06-28 | 2022-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000580A1 true CL2024000580A1 (es) | 2024-09-06 |
Family
ID=83447741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000580A CL2024000580A1 (es) | 2021-08-31 | 2024-02-26 | Vectores de hcmv recombinante y usos de estos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240384296A1 (https=) |
| EP (1) | EP4395809A1 (https=) |
| JP (1) | JP2024534189A (https=) |
| KR (1) | KR20240049807A (https=) |
| AU (1) | AU2022339765A1 (https=) |
| CA (1) | CA3226699A1 (https=) |
| CL (1) | CL2024000580A1 (https=) |
| CO (1) | CO2024001513A2 (https=) |
| IL (1) | IL310663A (https=) |
| MX (1) | MX2024001962A (https=) |
| TW (1) | TW202311531A (https=) |
| WO (1) | WO2023034801A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024059635A2 (en) * | 2022-09-13 | 2024-03-21 | Oregon Health And Science University | Universal t cell-based, cmv-vectored vaccine for influenza |
| CN120936375A (zh) * | 2023-04-14 | 2025-11-11 | 生物技术欧洲股份公司 | Hiv疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| DK2964769T3 (en) | 2013-03-05 | 2018-12-10 | Univ Oregon Health & Science | Cytomegalovirus vectors enabling control of T cell targeting |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| CN109843321A (zh) | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
| US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
| CN114402080B (zh) * | 2019-08-20 | 2024-09-13 | 俄勒冈健康与科学大学 | 人巨细胞病毒的ul18对t细胞应答的调节 |
-
2022
- 2022-08-30 JP JP2024513410A patent/JP2024534189A/ja active Pending
- 2022-08-30 US US18/687,050 patent/US20240384296A1/en active Pending
- 2022-08-30 WO PCT/US2022/075670 patent/WO2023034801A1/en not_active Ceased
- 2022-08-30 KR KR1020247006599A patent/KR20240049807A/ko active Pending
- 2022-08-30 EP EP22777537.6A patent/EP4395809A1/en active Pending
- 2022-08-30 MX MX2024001962A patent/MX2024001962A/es unknown
- 2022-08-30 IL IL310663A patent/IL310663A/en unknown
- 2022-08-30 CA CA3226699A patent/CA3226699A1/en active Pending
- 2022-08-30 AU AU2022339765A patent/AU2022339765A1/en active Pending
- 2022-08-30 TW TW111132771A patent/TW202311531A/zh unknown
-
2024
- 2024-02-13 CO CONC2024/0001513A patent/CO2024001513A2/es unknown
- 2024-02-26 CL CL2024000580A patent/CL2024000580A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3226699A1 (en) | 2023-03-09 |
| JP2024534189A (ja) | 2024-09-18 |
| US20240384296A1 (en) | 2024-11-21 |
| EP4395809A1 (en) | 2024-07-10 |
| AU2022339765A1 (en) | 2024-01-25 |
| CO2024001513A2 (es) | 2024-03-07 |
| IL310663A (en) | 2024-04-01 |
| KR20240049807A (ko) | 2024-04-17 |
| MX2024001962A (es) | 2024-03-01 |
| WO2023034801A1 (en) | 2023-03-09 |
| TW202311531A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000580A1 (es) | Vectores de hcmv recombinante y usos de estos | |
| AR110632A1 (es) | Vectores del adenovirus canino | |
| CO2019014677A2 (es) | Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos | |
| MX2018007198A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| PE20221758A1 (es) | Composiciones y metodos para la induccion de una respuesta inmune | |
| PY1548374A (es) | Vacunas de FMDV recombinante y usos de las mismas | |
| CO2022004470A2 (es) | Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos | |
| AR134554A2 (es) | Composición inmunológica o de vacuna y método para producir una respuesta protectora contra prrsv en un animal | |
| MX2014006360A (es) | Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos. | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| MX2018015787A (es) | Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado. | |
| BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. | |
| UY36995A (es) | Proteínas de fusión de e2 y fmdv y sus usos | |
| ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| BR112022019411A2 (pt) | Composições de vacina estabilizadas | |
| CL2021003328A1 (es) | Composiciones que comprenden iga secretora y probióticos. | |
| CL2019000705A1 (es) | Nuevos promotores. | |
| CL2024000600A1 (es) | Vacunas contra la tuberculosis | |
| CL2020002246A1 (es) | Expresión de proteína de superficie a neumocócica (pspa) | |
| CL2025000384A1 (es) | Proteína g antirrábica y sus usos | |
| UY36020A (es) | Antígeno de inhibina alfa, gen codificante de inhibina alfa, gen codificante de proteína de fusión, proceso de obtención del antígeno de inhibina alfa, composición antigénica, uso del antígeno de inhibina alfa y uso de la composición antigénica | |
| MX2026002232A (es) | Vectores cdv aiv y usos de los mismos | |
| UY36860A (es) | Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos | |
| UY36328A (es) | Vacunas de fmdv recombinante y usos de las mismas |